AstraZeneca's COVID Vaccine On Hold: A Reminder Drug Development Is Never Straightforward

The company – one of the frontrunners in the race to develop a COVID-19 vaccine – has voluntarily put a hold on the Phase III trial due to an adverse event. 

Stop barrier
AZ/Oxford vaccine on hold • Source: Shutterstock

AstraZeneca PLC and the University of Oxford have put a voluntary clinical trial hold on the Phase III trial testing their COVID-19 vaccine due to an adverse event. The companies confirmed the move in the evening on 8 September, only about a week after initiating the Phase III trial in the US.

While the development of several COVID-19 vaccines across the industry has been moving at an unprecedented pace and remarkably smoothly...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip